Introduction
WHO's preferred first-line antiretroviral therapy (ART) regimen for adults and adolescents with HIV is the second-generation integrase strand transfer inhibitor dolutegravir, combined with tenofovir and lamivudine or emtricitabine.Implementing an additional dose of dolutegravir with antituberculosis therapy is challenging in high-burden settings, illustrated by the finding of a Botswanan study in which standard-dose dolutegravir was used in almost half of patients on dolutegravir-based ART during antituberculosis therapy, despite national guidelines recommending double-dose dolutegravir.
